'Systemic' changes coming to advisory committee process, FDA commissioner says

Zachary Brennan

Senior Editor

The FDA is preparing to release “systemic” changes to its advisory committee process, Commissioner Rob Califf said Wednesday, building on months of hints that a high-profile part of the drug review process might face major reforms.

Califf offered few details other than saying that top leaders at the agency are still trying to reach an agreement on what changes are likely. The work is being led by Namandjé Bumpus, the FDA’s chief scientist and newly named deputy commissioner, he added at the Alliance for a Stronger FDA event.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

'Systemic' changes coming to advisory committee process, FDA commissioner says

Zachary Brennan

Senior Editor

Unlock this article instantly by becoming a free subscriber.

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

Medical Affairs: The Critical Link Between Science, Physicians and Patients

'Sys­temic' changes com­ing to ad­vi­so­ry com­mit­tee process, FDA com­mis­sion­er says

Zachary Brennan

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

In­side CVS Care­mark’s move that broke Hu­mi­ra’s hold on the mar­ket

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

Pa­tient dies in Pfiz­er’s Phase 2 Duchenne mus­cu­lar dy­s­tro­phy tri­al

'Big­ger, faster, bet­ter': Iso­mor­phic, Deep­Mind un­veil Al­phaFold 3, go­ing be­yond pro­tein pre­dic­tions

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

'Systemic' changes coming to advisory committee process, FDA commissioner says

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

Medical Affairs: The Critical Link Between Science, Physicians and Patients